if they experience nausea, vomiting or abdominal pain)
[DOI] [PubMed] [Google Scholar] 147.Potischman N., Salazar S., Susser J., Saldanha L., Dwyer J., Kuzak A., Betz J., Bailen R
including semaglutide branded as Wegovy or Ozempic, and tirzepatide (dual GIP/GLP-1 receptor agonist) branded as Zepbound or Mounjaro, for the management of obesity, type 2 diabetes, and other metabolic conditions increases, so too does the need to assess the advantages and potential downsides of long-term use
August 18th, 2025: FDA Flags Rising Safety Concerns Over Compounded and Counterfeit Ozempic and GLP-1 Drugs The FDA has issued a new warning highlighting the dangers of unapproved and compounded GLP-1 receptor agonists, including versions of semaglutidethe active ingredient in Ozempic and Wegovy